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Abstract
Background: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder associated with inborn errors
of steroid metabolism. 21-hydroxylase enzyme deficiency occurs in 90 to 95% of all cases of CAH, with accumulation of
17 hydroxyprogesterone (17-OHP). Early diagnosis of CAH based on newborn screening is possible before the
development of symptoms and allows proper treatment, correct sex assignment, and reduced mortality rates.
This study describes the results obtained in the first year of a public CAH screening program in the state of Rio
Grande do Sul, Brazil.
Methods: We reviewed the screening database in search of babies with suspected CAH, that is, altered birth-
weight adjusted 17-OHP values at screening. The following data were analyzed for this population: screening
17-OHP values, retest 17-OHP values, serum 17-OHP values for those with confirmed CAH on retest, maternal and
newborn data, and family history of CAH. For the screening program, 17-OHP levels are determined on dried
blood spots obtained in filter paper with GSP solid phase time-resolved immunofluorescence.
Results: Of 108,409 newborns screened, eight were diagnosed with CAH (four males, four females). The incidence of CAH
in the state was 1:13,551. Six cases were identified as classic salt-wasting CAH and two were cases of virilizing CAH. The
positive predictive value (PPV) of the initial screening (before diagnostic confirmation) was 1.6%. The overall rate of false
positive results was 0.47%. The number of false positive results was higher among newborns with birth weight < 2000 g.
Conclusion: The present results support the need for CAH screening by the public health care system in the state,
and show that the strategy adopted is adequate. PPV and false positive results were similar to those reported for other
states of Brazil with similar ethnic backgrounds.
Keywords: Congenital adrenal hyperplasia, Incidence, Neonatal screening, Mass screening, 21-amino-17-
hydroxyprogesterone
Background
Congenital adrenal hyperplasia (CAH) is an autosomal
recessive disorder associated with inborn errors of
steroid metabolism caused by deficiency of enzymes
involved in the biosynthesis of cortisol from cholesterol
[1]. 21-hydroxylase deficiency occurs in 90 to 95% of all
cases of CAH and is related to mutations in the
CYP21A2 gene [1, 2]. In the presence of 21-hydroxylase
deficiency, 17 hydroxyprogesterone (17-OHP) accumu-
lates and is diverted to androgen synthesis with virilizing
effects [1, 2]. Mineralocorticoid synthesis may or may
not be reduced, depending on the extent to which 21-
hydroxylase activity is impaired [1, 3].
Three clinical forms of CAH have been recognized:
two classic forms, salt-wasting CAH (SW) and simple
virilizing CAH (SV), and non-classic, late onset CAH
(NC). SW is the most prevalent, occurring in around
75% of newborns with a diagnosis of CAH (1). Consider-
ing that the salt loss crisis is critical and starts in the
* Correspondence: simonecastro13@gmail.com
1Neonatal Screening Labor, Neonatal Screening Unit, Hospital Materno
Infantil Presidente Vargas, Porto Alegre, RS, Brazil
2Departamento de Análises, School of Pharmacy, Universidade Federal do
Rio Grande do Sul, Porto Alegre, RS, Brazil
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kopacek et al. BMC Pediatrics  (2017) 17:22 
DOI 10.1186/s12887-016-0772-x
second week of life, early diagnosis of classic forms of
CAH based on newborn screening is desirable even be-
fore the beginning of symptoms. This allows proper
treatment, correct sex assignment, and reduced mortal-
ity rates [2, 4, 5]. CAH occurs in about one of every
10,000 to 18,000 live births in the general population,
and is more common in Caucasians [1]. Incidence varies
according to ethnicity and geographical region [1, 6]. In
addition, 17-OHP levels in neonates are affected by fac-
tors such as gestational age at birth, birth weight, and
age at the time of 17-OHP testing [7–11]. Perinatal stress
has been associated with high values of 17-OHP on
screening [8, 12], while maternal use of corticosteroids to-
wards the end of pregnancy and early sample collection
seem to reduce these values [10, 13]. Reference 17-OHP
values for diagnosis of CAH in full term newborns vary
from 15 to 40 ng/mL among different laboratories.
Because of the many factors impacting the outcome of
CAH screening, the stratification of 17-OHP values ac-
cording to birth weight is recommended in order to de-
crease false positive results [8, 10, 14]. A high rate of
false positive results translates into increased health care
cost and distress for families [15–17].
Even though screening for CAH has been available
through the public health care system for many years in
some Brazilian states [10, 16, 18, 19], only in May 2014
was it introduced in the southernmost state of Rio
Grande do Sul. Therefore, the aims of the present study
were to summarize the results of the first year of CAH
newborn screening in this population, to determine the
incidence of CAH in the state, and to estimate the rate
of false positive results in the local screening program.
Methods
Design and population
A population-based study was conducted with newborns
included in the first year of a public CAH screening pro-
gram in the state of Rio Grande do Sul, Brazil (May 2014 to
April 2015). For the screening program, dried blood sam-
ples (heel prick test) are collected 2 to 40 days after birth.
Babies with positive screening are retested. Participation is
open to public and private primary care facilities, health
care units, hospitals, and maternity hospitals. The study
population corresponded to about three-fourths of the live
newborns in the state during this period. The other 25% of
newborn babies are screened in private outpatient services,
and data from this population are not freely available.
In the present study, we reviewed the screening data-
base in search of babies with suspected CAH, that is, al-
tered 17-OHP values at screening. The following data
were analyzed for this population: screening 17-OHP
values, retest 17-OHP values, serum 17-OHP values (for
those with suspected CAH on screening and retest), ma-
ternal and newborn data, and family history of CAH.
Figure 1 describes the screening strategy.
Fig. 1 Flow diagram of newborn screening for congenital adrenal hyperplasia
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The study protocol was approved by the Research Eth-
ics Committee at Hospital Materno Infantil Presidente
Vargas, and meets the guidelines and norms regulating
research involving human beings.
Blood collection and 17-OHP measurements
Dried blood spots were obtained using filter paper (S &
S 903). 17-OHP was measured with the GSP solid phase
[time-resolved] immunofluorescence assay (Neonatal 17-
OHP kit–PerkinElmer, Turku, Finland). The linearity
range for serum 17-OHP concentration was 0.9 to
229 ng/mL.
The reference 17-OHP values used in the present
study are those recommended by the Brazilian National
CAH Screening Program [20], which were based on a
pilot study with the population of the state of São Paulo
[10]. Four birth weight tiers were established: tier 1,
birth weight ≤ 1500 g; tier 2, birth weight 1501 to
2000 g; tier 3, birth weight 2001 to 2500 g; and tier 4,
birth weight > 2500 g. For each tier, the 99th percentile
(P99) 17-OHP cut-off levels to diagnose CAH were
110.4, 43.0, 28.2 and 15.1 ng/mL respectively. In the
pilot study, newborns from mothers with informed cor-
ticosteroid use late in pregnancy were called for a sec-
ond collection after 15 days of life. This record was
added to the filter paper in order to minimize the risk of
false negative results [13]. For the present study, early
(<48 h) samples collected for 17-OHP determinations
were excluded. In the Rio Grande do Sul screening pro-
gram, CAH screening is based on samples collected be-
tween the 2nd and 40th post-natal days. Samples from 0
to 1 days and/or without weight information were ex-
cluded from this analysis, but these babies were called
for immediate new collection in the valid period and
with correct weight information.
Classic CAH (SW and SV) was diagnosed by increased
17-OHP on screening, confirmed by dried blood spot
retest and further clinical evaluation showing virilized
external genitalia in girls and salt-wasting signs in both
sexes and serum/dried blood spot 17-OHP measurement.
Statistical analysis
Descriptive data were expressed as mean ± standard de-
viation (SD) or median and 25–75 interquartile range.
Categorical variables are reported as frequencies (%).
Log10 transformation was used to normalize the distri-
bution of non-Gaussian variables and Student’s t test
was used for comparisons between two groups. Categor-
ical variables were compared using Fisher’s exact test.
Generalized estimating equations (GEE) were used to es-
timate the interaction between birth weight tier and the
difference (delta) between 17-OHP levels at screening
and retest, followed by Bonferroni test. All analyses were
performed using the Statistical Package for the Social
Sciences 22.0 (SPSS, Armonk, NY, USA). Data were con-
sidered to be significant at p < 0.05.
Results
Of the 108,409 total samples obtained at the initial
screening, 104,737 were collected between the 3rd and
40th post-natal days, and included in the present ana-
lysis, corresponding to 98.4% of the total. Of these,
83,424 (77%) were collected at age 3–7 days. Most retest
samples were collected around the second or third week
of life [median 17 (14.0–21.0) days]. Eight newborns
were diagnosed with CAH (four males, four females).
None of the four females had a clinical diagnosis of
CAH prior to the screening: the first female presented
genital ambiguity of unknown etiology; the second was
initially considered as a male; and in the other two fe-
males, clitoromegaly was not recognized. Two deaths oc-
curred, one due to complications associated with several
malformations and the other due to hyponatremia and
metabolic acidosis. In this child, screening was not per-
formed until 38 days of life.
The incidence of CAH in the state was 1:13,551. Six
cases were identified as classic salt-wasting CAH and two
were cases of virilizing CAH. Figure 2 shows the incidence
of CAH in the state and in the other Brazilian states.
During this first year, 514 infants (0.47% of the total
screened population) had 17-OHP levels that were
higher than the reference cut-off levels (>P99 or two
times P99 for each birth weight tier) on the screening
test. Of these 514 infants, 21 died before retest from
various causes, of which extreme prematurity was the
most frequent (mean weight 1.413,4 ± 970,4) and 376
(73%) had normal 17-OHP levels on retest. The
remaining 117 infants with suspected CAH at retest
were examined by a pediatrician and underwent serum
or dried blood measurement of 17-OHP. CAH diagnosis
was confirmed in eight infants. One of them initiated
treatment before the second sample collection. Clinical
and laboratory assessment of the other 109 patients
(0.1% of the total population) was negative, and the pa-
tients were considered to be FP.
The estimated positive predictive value (PPV) of the
initial screening test was 1.6%. Table 1 shows the rates
of altered 17-OHP values at the initial screening accord-
ing to birth weight tier in the general population
screened until 40 days of age.
Median age was similar for CAH cases and false posi-
tive at the initial screening (n = 493) [8 (4.25–15.75) and
5 (4.0–6.0) days P = 0.199] and at retest (n = 492) [20.0
(17–20.0) and 17 (14–21) days, P = 0.205]. Median 17-
OHP values at initial screening were significantly
different between CAH cases and false positive
[446.50 ng/mL (72.60–501.25) and 25.80 (17.4–41.8) ng/mL;
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p= 0.001]. The same was true for the retest, with a 17-OHP
median of 435 ng/mL (209–521) and 8.30 (5.86–12.60)
ng/mL (p < 0.001) respectively.
Table 2 shows 17-OHP values at the initial screening
and retest according to birth weight tier. At the initial
screening test as wells as at the retest, 17-OHP values
were progressively lower with increasing weight. Delta 17-
OHP levels (retest minus screening value) were also
significantly different in each tier compared to the others.
Regarding the 117 infants who underwent further clin-
ical and laboratory evaluation of CAH, 61.5% (n = 72)
were in birth weight tier 4 (>2500 g), vs. 7.7% (n = 9) in
tier 1, 13.6% (n = 16) in tier 2, and 17% (n = 20) in tier 3.
No CAH case was diagnosed in tier 1 or 2, with birth
weight < 2000 g. The prevalence of maternal complica-
tions, such as gestational diabetes, maternal hypertension,
or maternal infection was similar in the case and false
positive groups. The frequency of neonatal complications
(hypoglycemia, jaundice, sepsis, ventilation, oxygen ther-
apy, diarrhea, vomiting) was also similar between these
two groups. Comparison of the clinical and laboratory
data obtained for cases and babies with false positive re-
sults are presented in Table 3. Significant differences were
observed between the groups, with higher prematurity
rate, lower gestational age, and lower weight in false
positive patients. In turn, consanguinity and dehydration
were more frequent in CAH cases. Also, lower levels of
sodium, higher levels of potassium and higher serum
levels of 17-OHP were detected in CAH patients, as was
to be expected.
Discussion
Early diagnosis of CAH is crucial to prevent infant death
due to adrenal insufficiency. In the present study, the
first year of a CAH screening program provided by the
public health care system in the state of Rio Grande do
Sul, Brazil was assessed. The program successfully
screened a high proportion of newborns (98.4%) between
the 2nd and 40th post-natal days, and 80% of the valid
Table 1 Rate of altered 17-OHP results on initial CAH screeninga
stratified by birth weight tier in the general population tested
until 40 days of age in the state of Rio Grande do Sul, Brazil
Birth weight tier Number 17 OHP (>P99 or two times P99)
n (%)
≤1500 g 1071 35 (3.3%)
1501–2000 g 1773 71 (4.0%)
2001–2500 g 6462 106 (1.6%)
≥2501 g 95,431 302 (0.3%)
Total 104,737 514 (0.5%)
a17-OHP diagnostic cut-off levels: birth weight ≤ 1500 g: 110.4 ng/mL; birth
weight 1501 to 2000 g: 43.0 ng/mL; birth weight 2001 to 2500 g: 28.2 ng/mL;
and birth weight weight > 2500 g: 15.1 ng/mL
Fig. 2 Reported incidence of CAH at neonatal screening in different states of Brazil
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samples were screened at the ideal moment, that is, be-
tween the 3rd and 7th post-natal days [2, 4, 10].
The incidence of CAH in the state of Rio Grande do
Sul detected by the screening program, 1:13,551, was
similar to that reported for other populations [1]. It was
also very close to the incidence of 1:14,972 reported for
the only adjacent Brazilian state, in which a similar, pre-
dominantly Caucasian population is found [19]. In con-
trast, other Brazilian states had a lower incidence of
CAH [16, 17]. Ethnicity and geographic factors are
known to affect the incidence of CAH [1, 6]. Thus, in a
country such as Brazil, covering a large territory, with a
racially mixed population, different ratios are to be ex-
pected. According to the latest Brazilian census, of 2010,
78% of the population in the South is white, in contrast
to 42% in the Midwest and 55% in the Southeast [21].
Regarding confirmed CAH cases, the inability to diag-
nose the disease even in the presence of genital atypia
has been reported in other Brazilian studies [10], and
reinforces the need for universal newborn screening for
CAH in Brazil. In this sense, improving time to test,
transport time to the laboratory, and time to result is
still a challenge that must be overcome. In turn, the
15 day-interval to retest seems to be adequate in most
cases, since these are premature newborns, hospitalized
in intensive care units, born from mothers who may
have received corticoids during the final pregnancy days
for improving fetal lung maturation.
Since 1977, when Pang et al. [22] described a microfil-
ter paper assay for determination of 17-OHP levels in
newborns, neonatal screening has been available for
CAH due to 21-hydroxylase deficiency. Later, an immu-
nofluorimetric assay was introduced, which is currently
the most widely used technique worldwide [2, 23, 24].
More recent studies suggest a higher specificity and bet-
ter sensitivity for mass spectrometry, especially when
used as a second tier test [25–27]. In contrast, immuno-
fluorimetric methods are less expensive, require a
Table 2 Median 17-OHP levels in infants with suspected congenital adrenal hyperplasia on newborn screening and retest according
to birth weight tier








n = 298 §
Screening (median ng/mL [P25-75]) 154 (120 to 208)a 53.6 (47.0 to 64.7)b 33.6 (29.9 to 41.9)c 18.8 (16.0 to 23.4)d <0.001
Retest (median ng/mL [P25-75]) 48.1 (21.9 to 96.5)a 12.7 (10.1 to 20.5)b 8.1 (6.4 to 12.3)c 7.3 (5.1 to 10.6)d <0.001
Δ Samples −98.6 (−172.5 to −67.0)a −38.9 (−47.2 to −33.2)b −24.9 (−31.5 to −21.2)c −11.8 (−15.6 to −7.95)d <0.001
#17-OHP diagnostic cut-off levels: birth weight ≤ 1500 g: 110.4 ng/mL; birth weight 1501 to 2000 g: 43 ng/mL; birth weight 2001 to 2500 g: 28.2 ng/mL; and birth
weight weight > 2500 g: 15.1 ng/mL; §n = 297 on retest
Δ Samples: difference between 17-OHP at retest and screening
Values are expressed as median and interquartile range; different superscript letters indicate statistical difference by GEE test
Table 3 Family history, maternal, perinatal, newborn and laboratory data of newborns diagnosed with congenital adrenal







Caesarean delivery (n [%]) 4/8 (50.0) 42/70 (60.0) 0.496
Newborn data
ICU care (n [%]) 4/8 (50.0) 71/98 (72.4) 0.281
Preterm (n [%]) 2/8 (25.0) 59/109 (54.1) 0.004
Birth weight (n [%]) 2940 ± 570.34 (n = 8) 2496 ± 761.63 (n = 109) 0.110
Gestational age (week) 38.0 ± 1.9 (n = 8) 34.8 ± 3.2 (n = 72) 0.007
Dehydration (n [%]) 5/8 (62.5) 3/76 (3.9) <0.001
Na (nmol/L)a 122.25 ± 10.15 (n = 8) 136.56 ± 2.28 (n = 54) 0.005
K (nmol/L)a 6.17 ± 1.21 (n = 8) 5.31 ± 0.67 (n = 54) 0.004
Serum 17-OHP (ng/mL) (Md [P25-P75]) 25.6 (12.8–285) (n = 3) 12.5 (7.4–17.8) (n = 45) 0.006
Family data
Family history (n [%]) 3/8 (37.5) 9/67 (13.4) 0.196
Consanguinity (n [%]) 2/8 (25.0) 0/109 (0%) <0.001
CAH Congenital adrenal hyperplasia, ICU Intensive care unit. Data are presented as percentage (Fisher’s exact test) or amean ± SD (Student’s t test)
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smaller blood spot, and are still widely available and rec-
ommended [2, 10, 24]. Also, mass spectrometry does not
completely eliminate false positive results, especially in
preterm infants [14, 27] .
In our sample, PPV (1.6%) and false positive rate were
similar to those of previous reports [10, 24, 28]. False
positive results are a long-standing concern of CAH
neonatal screening programs [7, 9–11, 23, 27, 29]. In the
past two decades, a decrease in false positive rates has
been noted [10, 11, 23, 29, 30], possibly as a result of
both improved 17-OHP detection methods and adjust-
ment of diagnostic cut-off points to birth weight [7, 10].
Adjustment of diagnostic levels of 17-OHP according to
birth weight tiers [7, 9, 10, 19] has been proposed as a
useful strategy to minimize false positive. However, it is
also important to recognize other possible factors associ-
ated with an increased 17-OHP level in newborns.
Indeed, studies have shown that low birth weight,
premature or critically ill infants may have elevated 17-
OHP levels per se, without a link to 21-hydroxylase defi-
ciency [8, 12, 31]. Possible explanations for the transient
elevation in 17-OHP levels in these patients are imma-
ture hepatic function, leading to a decrease in the meta-
bolic clearance of 17-OHP; increase in stress-induced
production of 17-OHP, especially if the sample is col-
lected in the first 24 h of life; or immaturity of the
adrenal glands [31, 32]. Low birth weight, premature,
and critically ill infants should be monitored in relation
to 17-OHP concentrations, with a second sample col-
lected on a later occasion to prevent false diagnoses and
waste of resources.
We found an association between low birth weight
and false positive results. The highest rate of false posi-
tive (4.0%) was found in the group with birth weight of
1500–2000 g (tier 2), in which no cases of CAH were fi-
nally detected (Table 1). We speculate that survival is
more likely in tier 2 newborns as compared to those in
tier 1 (<1500 g). We also recorded a higher rate of false
positive results in preterm versus term infants (Table 3).
Moreover, the gestational age of false positive babies was
significantly lower than that of CAH cases. While a high
correlation exists between birth weight and gestational
age, one study suggests that gestational age-related 17-
OHP cutoff levels improve CAH screening [9]. Never-
theless, birth weight data is more easily assessed than
gestational age. Coulm et al. reported a PPV of 0.4% for
CAH screening in pre-term infants, a value that is lower
than that observed for term infants. Another study [33]
suggests a correction factor for prematurity and weight,
but does not use stratified cut-offs, which complicates
the analysis of PPV. Interestingly, we observed that even
if above the diagnostic cut-off point for the birth weight
tier, 17-OHP values of false positive infants were signifi-
cantly lower than those of CAH cases in both the initial
screening and retest. Other studies have reported similar
findings [10, 19], which might be explained by a more
severe clinical status, since many of these false positive
infants required intensive care [12].
Consanguinity was an important factor in this popula-
tion, present in 25% of CAH cases but absent in false
positive cases. Thus, adding information about consan-
guinity to the initial screening might support CAH diag-
nosis in the presence of high 17-OHP levels. Limitations
of this study are its retrospective nature, which pre-
vented the analysis of factors related to false positive
results, and the lack of proper information on initial
screening regarding prenatal use of glucocorticoid,
which might affect 17-OHP levels. Prospective studies
with adequate design are required for these analyses.
Conclusion
The screening of CAH remains a challenge, and the im-
plementation of an adequate screening flow makes
population programs more assertive. In addition to the
17-OHP dosing method, diagnostic 17-OHP cut-offs
stratified by birth weight, collection of samples at spe-
cific time points, and performance of retests even in the
absence of clinical suspicion of CAH or confounding
factors, such as prematurity and critical illness, greatly
contribute to decrease false positive rates.
The present results support the need for CAH screen-
ing by the public health care system, and show that the
strategy adopted is adequate, despite the initial screening
of some infants after the 7th post-natal day. Future pro-
spective studies may be useful to establish specific strat-
egies for preterm groups, lower weight newborns, and
ICU patients, and to improve effectiveness and PPV in
all weight tiers.
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